Clinical Trial Search

Primary: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) — 23.29…

Primary: Diet Quality of Household Food Purchases — 57.88 units on a scale

Primary: 10 m Walk Test — 0.64; 0.79 m/s

Primary: Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events) — 5; 0; 0; 0 participants

Primary: Change From Baseline in Menopause Rating Scale Total Score — 6.3; 4.5 units on a scale — p=0.05

Primary: Change in Restless Legs Syndrome Quality of Life Instrument (RLSQoL) Over 4 Weeks — 78.92; 80.75; 77.75; 83.16 units on a scale

Primary: Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole — 1542.6; 1804.8 nmol/L

Primary: Prescription Understanding — 0.81; 0.82; 0.78 Probability

Primary: Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant — 0.42; 0.55; 0.57 Hour (h)

Primary: Number of Patients With Treatment-Emergent Adverse Events — 7; 6; 6; 6 Participants

Primary: Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9 — 2.53; 2.92; 3.93 Minutes

Primary: Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 — -0.16…

Primary: Pharmacokinetics(PK): Maximum Concentration (Cmax) of LY3314814 (AZD3293) — 194; 212; 164; 208 nanogram per milliliter (ng/mL)

Primary: The Neuropsychiatric Inventory (NPI). Measures the Frequency and Severity of Behavioral Symptoms in Dementia. — -38.1; 1.0; -12; -9.8 score on a scale — p=.02

Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 3.09 Percentage of Participants